Compare GFAI & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFAI | PMI |
|---|---|---|
| Founded | 2018 | 1981 |
| Country | Singapore | United States |
| Employees | 1657 | 75 |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 14.1M |
| IPO Year | N/A | N/A |
| Metric | GFAI | PMI |
|---|---|---|
| Price | $0.39 | $0.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 308.9K | ★ 6.3M |
| Earning Date | 04-21-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.11 |
| 52 Week High | $1.50 | $13.68 |
| Indicator | GFAI | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 37.92 |
| Support Level | $0.37 | $0.15 |
| Resistance Level | $0.60 | $0.27 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 42.67 | 18.51 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.